

# **Mechanism and management of pruritus in chronic cholestatic disorders**

---

Malaga, 24 May, 2019

Ulrich Beuers

Department of Gastroenterology and Hepatology  
Tytgat Institute of Liver and Intestinal Research  
Amsterdam University Medical Centers  
Location: Academic Medical Center  
Amsterdam  
The Netherlands

# **Disclosures**

**2014-2019**

---

## **Grant support**

German, Norwegian, American and South-African PSC patient foundations  
Netherlands Foundation of Gastroenterology and Hepatology (MLDS)  
EU project LIVERHOPE

## **Support for investigator-initiated studies**

Dr. Falk, Intercept

## **Consulting fees / Consulting without fees**

Intercept, Novartis, Shire / NGM

## **Lecture fees**


Abbvie, Falk Foundation, Gilead, Intercept, MSD, Novartis, Roche, Shire, Zambon

# Motus Circularis Bilis


Mauritius Reverhorst  
1690




Giovanni Alfonso Borelli  
1710



# Impairment of Bile Secretion may Induce Pruritus



Sherlock and Summerfield, 1979



# Causes of Pruritus in Cholestasis

## Intrahepatic cholestasis of pregnancy


Hormones

Drugs

BRIC / PFIC


Alcohol

HCV




# Pruritus in Primary Biliary Cholangitis

- *Diurnal variation* -



# The Itch Neuron



**GRP**, gastrin releasing peptide

**LPA**, lysophosphatidic acid


**Mrg**, Mas-related G protein coupled receptor

**Nppb**, natriuretic polypeptide b

**TGR5**, G protein coupled bile acid receptor

**Trp**, transient receptor potential

# The Itch Neuron



**GRP**, gastrin releasing peptide

**LPA**, lysophosphatidic acid

**Mrg**, Mas-related G protein coupled receptor

**Nppb**, natriuretic polypeptide b


**TGR5**, G protein coupled bile salt receptor

**Trp**, transient receptor potential

# Potential Pruritogens in Cholestasis

Pruritogens...

accumulate in the  
systemic circulation



# Pruritus in Cholestasis

## - Therapy 2019 -

Evidence

<b>1<sup>st</sup> line :</b>	• Cholestyramine (1-2 x 4 g/d, max. 16 g/d)	II-2 / B1
<b>2<sup>nd</sup> line :</b>	• Rifampicin (2 x 150 – 300 mg/d)	I / A1
<b>3<sup>rd</sup> line :</b>	• Naltrexone (25 - 50 mg/d)	I / B1
<b>4<sup>th</sup> line :</b>	• Sertraline (75 - 100 mg/d)	II-2 / C2

- Experimental**
- Cannabinoids
  - UV light therapy
  - Albumin dialysis
  - Nasobiliary drainage
  - Liver transplantation

Categories of evidence:

- I Randomized controlled trial
- II-1 Controlled trials without randomization
- II-2 Cohort or case-control analytic studies
- II-3 Multiple time series, dramatic uncontrolled experiments
- III Opinions of respected authorities, descriptive epidemiology

Evidence grading:

A: High quality; B: Moderate quality; C: Low quality

Recommendation:

1: Strong; 2: Weak

# Pruritus in Cholestasis

## - Therapy 2019 -

Evidence


<i>1<sup>st</sup> line :</i>	<ul style="list-style-type: none"><li>• Cholestyramine (1-2 x 4 g/d, max. 16 g/d)</li></ul>	II-2 / B1
<i>2<sup>nd</sup> line :</i>	<ul style="list-style-type: none"><li>• Rifampicin (2 x 150 – 300 mg/d)</li></ul>	I / A1
<i>3<sup>rd</sup> line :</i>	<ul style="list-style-type: none"><li>• Naltrexone (25 - 50 mg/d)</li></ul>	I / B1
<i>4<sup>th</sup> line :</i>	<ul style="list-style-type: none"><li>• Sertraline (75 - 100 mg/d)</li></ul>	II-2 / C2

### *Experimental*


- Cannabinoids, Ondansetron
- UV light therapy
- **Albumin dialysis (e.g. MARS<sup>R</sup>); plasma separation/anion absorption**
- Nasobiliary drainage
- Liver transplantation

# Severe Refractory Pruritus in Cholestasis

## - Experimental Therapeutic Approaches -



Pares et al., J Hepatol 2010;53:307



Plasmapheresis <sup>1</sup>  
Albumin dialysis (MARS<sup>R</sup>, Prometheus<sup>R</sup>) <sup>2</sup>  
Plasma separation / anion absorption <sup>3</sup>


1. Cohen et al., Gut 1985; 26 (3); 291

2. Pares et al., Am J Gastroenterol 2004;99:1105, J Hepatol 2010;53:307

3. Pusl et al., J Hepatol 2006;45:887

# Potential Pruritogens in Cholestasis

Pruritogens...



# Pruritus in Cholestasis

## - Therapy 2019 -

Evidence

**1<sup>st</sup> line :** • Cholestyramine (1-2 x 4 g/d, max. 16 g/d) II-2 / B1

**2<sup>nd</sup> line :** • Rifampicin (2 x 150 – 300 mg/d) I / A1

**3<sup>rd</sup> line :** • Naltrexone (25 - 50 mg/d) I / B1

**4<sup>th</sup> line :** • Sertraline (75 - 100 mg/d) II-2 / C2

**Experimental**

- Cannabinoids
- UV light therapy
- Albumin dialysis
- **Nasobiliary drainage**
- Liver transplantation

### Categories of evidence:

- I Randomized controlled trial
- II-1 Controlled trials without randomization
- II-2 Cohort or case-control analytic studies
- II-3 Multiple time series, dramatic uncontrolled experiments
- III Opinions of respected authorities, descriptive epidemiology

### Evidence grading:

A: High quality; B: Moderate quality; C: Low quality


### Recommendation:

1: Strong; 2: Weak

# Severe Refractory Pruritus in Cholestasis


## - Experimental Therapeutic Approaches -

### Nasobiliary drainage in PBC



# Potential Pruritogens in Cholestasis

Pruritogens...



# Pruritus in Cholestasis

## - Therapy 2019 -

Evidence

<b>1<sup>st</sup> line :</b>	• Cholestyramine (1-2 x 4 g/d, max. 16 g/d)	II-2 / B1
<b>2<sup>nd</sup> line :</b>	• <b>Rifampicin (2 x 150 – 300 mg/d)</b>	I / A1
<b>3<sup>rd</sup> line :</b>	• Naltrexone (25 - 50 mg/d)	I / B1
<b>4<sup>th</sup> line :</b>	• Sertraline (75 - 100 mg/d)	II-2 / C2

### Categories of evidence:

- I Randomized controlled trial
- II-1 Controlled trials without randomization
- II-2 Cohort or case-control analytic studies
- II-3 Multiple time series, dramatic uncontrolled experiments
- III Opinions of respected authorities, descriptive epidemiology

### Evidence grading:

A: High quality; B: Moderate quality; C: Low quality

### Recommendation:

1: Strong; 2: Weak

# Potential Pruritogens in Cholestasis

Pruritogens...

accumulate in the systemic circulation

Albumin dialysis etc.

affect the endogenous serotonergic and opioidergic system


Rifampicin

are (biotrans-)formed in the liver and/or gut

are secreted into bile

Nasobiliary drainage

Cholestyramine



# Pruritus in Cholestasis

## - Therapy 2019 -

Evidence

<b>1<sup>st</sup> line :</b>	<ul style="list-style-type: none"><li>• Cholestyramine (1-2 x 4 g/d, max. 16 g/d)</li></ul>	II-2 / B1
<b>2<sup>nd</sup> line :</b>	<ul style="list-style-type: none"><li>• Rifampicin (2 x 150 – 300 mg/d)</li></ul>	I / A1
<b>3<sup>rd</sup> line :</b>	<ul style="list-style-type: none"><li>• <b>Naltrexone (25 - 50 mg/d)</b></li></ul>	I / B1
<b>4<sup>th</sup> line :</b>	<ul style="list-style-type: none"><li>• <b>Sertraline (75 - 100 mg/d)</b></li></ul>	II-2 / C2

### Categories of evidence:

- I Randomized controlled trial
- II-1 Controlled trials without randomization
- II-2 Cohort or case-control analytic studies
- II-3 Multiple time series, dramatic uncontrolled experiments
- III Opinions of respected authorities, descriptive epidemiology

### Evidence grading:


**A:** High quality; **B:** Moderate quality; **C:** Low quality

### Recommendation:

1: Strong; 2: Weak

# Therapeutic Targets in Pruritus of Cholestasis

Pruritogens...



# What causes Pruritus in Cholestasis?



***Aretaeus the Cappadocian***

(1<sup>st</sup> century A.C.)


‘Pruritus in jaundiced patients is caused by prickly biliary particles’

# Which substance classifies as pruritogen in cholestasis?


---

- Bile salt
- Bilirubin
- Endogenous  $\mu$ -opioid
- Fatty acid
- Histamin
- Lysophosphatidic acid (LPA) / autotaxin (ATX)
- Neuropeptides (substance P, calcitonin gene-RP)
- Serotonin
- Steroid metabolite


# Identification of a Neuronal Activator in Serum of Pruritic Patients




# Intradermal LPA Increases Scratching Behaviour in Mice



# Lysophosphatidic Acid (LPA) is Elevated in Serum of Pruritic Patients




# Lysophosphatidic Acid (LPA) is Formed by Autotaxin in Serum




# Increased Autotaxin Activity is rather specific for Pruritus of Cholestasis

A




\* p<0.05, \*\*\* p<0.001 (ANOVA)

# Linear Correlation between Autotaxin Activity and Itch Intensity











# Autotaxin Activity Mirrors Therapeutic Efficacy in Pruritus of Cholestasis

## Itch




# Autotaxin Activity mirrors Therapeutic Efficacy in Pruritus of Cholestasis

## Itch











## ATX

# Correlation between Change in Autotaxin Activity and Itch Intensity




# Autotaxin Activity mirrors Therapeutic Efficacy in Pruritus of Cholestasis




# Rifampicin stimulates detoxification capacity in liver and intestine via the pregnane X receptor (PXR)

Rifampicin




# Autotaxin mRNA Expression *in vitro* is downregulated by Rifampicin via Pregnan X Receptor (PXR)-dependent Mechanisms


A



B




C





# Persistent hepatocellular secretory failure (PHSF)

- Serum bilirubin >255 µmol/L (>15 mg/dL)
- Persistently elevated bilirubin (>1 week) after removal of the underlying cause (medication, toxin, transient mechanical obstruction)
- Exclusion of bile duct obstruction by imaging
- No underlying liver disease
- Rapid response to rifampicine



# Enterendoocrine Cells are a Potential Source of Autotaxin in Man



Mouse

Man

# Therapeutic Targets in Pruritus of Cholestasis

“Actual treatment”

Pruritogens...

accumulate in the systemic circulation

Albumin dialysis etc.

affect the endogenous serotonergic and opioidergic system

Naltrexone  
Sertraline

Rifampicin

are (biotrans-)formed in the liver and/or gut

Autotaxin → LPA

Rifampicin\*

are secreted into bile


Nasobiliary drainage

Cholestyramine

# Pruritus of Cholestasis

Actual and potential future treatment

Pruritogens...



# Which substance classifies as pruritogen in cholestasis?


---

- Bile salt
- Bilirubin
- Endogenous  $\mu$ -opioid
- Fatty acid
- Histamin
- Lysophosphatidic acid (LPA) / autotaxin (ATX)
- Neuropeptides (substance P, calcitonin gene-RP)
- Serotonin
- Steroid metabolite

# Pruritus of Cholestasis

Actual and potential future treatment

Pruritogens...



# Identification of a Neuronal Activator in **Bile** of Pruritic Patients


---

?


# Pruritus of Cholestasis

Actual and potential future treatment


Pruritogens...



# The ASBT inhibitor GSK2330672 improves pruritus in primary biliary cholangitis




# No Correlation between Serum Bile Salts and Itch Intensity



# Pruritus of Cholestasis

Actual and potential future treatment


Pruritogens...



# Pruritus of Cholestasis

Actual and potential future treatment

Pruritogens...



# **Pruritus of Cholestasis**

## **Mechanisms and management**

**Three of many open questions:**

- **What is the role of the hepatocyte, cholangiocyte and ileocyte in pruritus of cholestasis ?**
- **What is the biliary factor X in pruritus of cholestasis ?**
- **How do ASBT inhibitors and PPAR agonists ameliorate pruritus in cholestasis ?**

**Thank  
you**

## Tytgat Institute for Liver and Intestinal Research & AMC, Amsterdam

Germany

Andreas Kremer, Ruth Bolier, Dagmar Tolenaar, Remco van Dijk, Jacqueline Langedijk

Christian Rust

Ronald Oude Elferink



Spain

Albert Pares

Belgium

Tania Roskams

Mina Komura

NKI, Amsterdam

Wouter Moolenaar

UMC, Utrecht

Karel J. van Erpecum

Erasmus MC, Rotterdam

Edith M. Kuiper

Maren Harms

Henk R. van Buuren

United Kingdom

Catherine Williamson

Rajiv Jalan

Lithuania

Jurate Kondrackiene



ZonMW



Amsterdam UMC  
University Medical Centers